unknown
Stage
1
Investors
About
Bugworks develops antibiotic discovery technologies to overcome efflux-mediated drug resistance and enable entry of antibiotics into Gram-negative pathogens. The company has generated multiple novel antibacterial chemical series that it reports are now at clinical stages and is a recipient of CARB-X funding.
Explore Bugworks's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.